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Abstract
Background: Debate is intensifying about how to assess the full range of impacts from medical research.
Complexity increases when assessing the diverse funding streams of funders such as Asthma UK, a charitable
patient organisation supporting medical research to benefit people with asthma. This paper aims to describe the
various impacts identified from a range of Asthma UK research, and explore how Asthma UK utilised the
characteristics of successful funding approaches to inform future research strategies.
Methods: We adapted the Payback Framework, using it both in a survey and to help structure interviews,
documentary analysis, and case studies. We sent surveys to 153 lead researchers of projects, plus 10 past research
fellows, and also conducted 14 detailed case studies. These covered nine projects and two fellowships, in addition
to the innovative case studies on the professorial chairs (funded since 1988) and the MRC-Asthma UK Centre in
Allergic Mechanisms of Asthma (the ‘Centre’) which together facilitated a comprehensive analysis of the whole
funding portfolio. We organised each case study to capture whatever academic and wider societal impacts
(or payback) might have arisen given the diverse timescales, size of funding involved, and extent to which Asthma
UK funding contributed to the impacts.
Results: Projects recorded an average of four peer-reviewed journal articles. Together the chairs reported over 500
papers. All streams of funding attracted follow-on funding. Each of the various categories of societal impacts arose
from only a minority of individual projects and fellowships. Some of the research portfolio is influencing asthma-
related clinical guidelines, and some contributing to product development. The latter includes potentially major
breakthroughs in asthma therapies (in immunotherapy, and new inhaled drugs) trialled by university spin-out
companies. Such research-informed guidelines and medicines can, in turn, contribute to health improvements. The
role of the chairs and the pioneering collaborative Centre is shown as being particularly important.
Conclusions: We systematically demonstrate that all types of Asthma UK’s research funding assessed are making
impacts at different levels, but the main societal impacts from projects and fellowships come from a minority of
those funded. Asthma UK used the study’s findings, especially in relation to the Centre, to inform research funding© 2013 Hanney et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Globally research funders are under growing pressure to
demonstrate the returns or impacts that arise from their
research funding [1-4]. In 2006, the UK Evaluation
Forum, which brought together the Academy of Medical
Sciences, the Medical Research Council (MRC) and the
Wellcome Trust, considered ways of assessing the bene-
fits of medical research and called for further studies [2].
For charitable patient organisations that fund medical re-
search it is increasingly important to demonstrate that the
money they have invested is leading to improvements in
the healthcare and quality of life of the patients they exist
to support [5]. Charities are accountable for this in a formal
way (for example, to regulators, funders or members) and
in a moral way (for example, to beneficiaries, service users,
partner charities, staff, volunteers and the general public).
Asthma UK (under its current and previous names)
has been funding research since 1927. Since the forma-
tion of the National Asthma Campaign in 1989, the
charity has spent over £50 million on research to under-
stand more about asthma, its causes and treatments. It
has been spending up to £3 million and funding between
ten and twenty new projects each year. Asthma UK has
historically provided various types of funding for re-
search, including long-term support for two professorial
chairs over the last twenty years, medium-term support
through a research fellowship scheme, and project sup-
port through an annual grant round. Since 2005 the
charity has jointly funded the pioneering collaborative
MRC-Asthma UK Centre in Allergic Mechanisms of
Asthma (the ‘Centre’) based at both King’s College
London and Imperial College London. Asthma UK has
more recently introduced funding for PhD studentships,
initially linked to the Centre.
Asthma UK has a relatively limited budget and so has
long engaged with the scientific community to help
identify the areas of research that would be most likely
to achieve its objectives [6]. However, in response to the
charity’s wider range of accountabilities, Asthma UK de-
cided to review various aspects of its role as a research
funder. These included, firstly, increasingly ensuring
people affected with asthma were meaningfully involved
in reviewing all proposals for funding, and, secondly,
building greater understanding of what had been
achieved through the breadth of its previous research
funding activities, so as to help inform an enhanced
research strategy. This article focuses primarily on the
latter, but provides some evidence related to the former.
Although the importance of charities being able to
demonstrate the impact of their research funding is
widely recognised, attempts to assess rigorously the im-
pact of research funding have been limited, and not just
for charitable research funders. This is largely due to the
huge difficulties of demonstrating impact in research,attributable to the fact that many pieces of research
might contribute to achieving some impacts, and a huge
time lag can be involved before tangible benefits are
realised [7].
Of the relatively small number of impact studies
reported in the literature, the Payback Framework devel-
oped by the Health Economics Research Group (HERG)
is described as the approach used most often [8-10]. It
constitutes a framework for addressing the conceptual
issues, and collecting, analysing and reporting data in a
reasonably consistent manner to capture the impacts
and outputs of research [8]. As such, the Payback
Framework has been used as a tool to help funders and
stakeholders in research to think about what the likely
impacts from research can or might be.
For a research funder there could be clear benefits in
having an assessment made of their full portfolio of
research funding. Yet, attempts to assess the impact of a
wide-ranging research funder’s full portfolio of research
are even rarer than assessment of selected case studies
or specific programmes. This is because they require the
combination of two different approaches:
 achieving breadth of coverage to give a reasonable
picture of the impacts from the full portfolio;
 conducting the detailed analyses needed to address
issues such as how far impacts can be attributed to
the specific research being examined.
Doing this rigorously requires the research instru-
ments (surveys and case studies adopting triangulation
techniques etc.) to be able to tackle issues such as
responders’ bias and selective recall.
In 2008, Asthma UK approached HERG to apply their
Payback Framework to identify the benefits that have
arisen from the charity’s various forms of research sup-
port and thereby help Asthma UK to continue to use its
funds to best effect in terms of maximising benefits for
people with asthma in its future research strategy. The
team from HERG and RAND Europe conducting the in-
dependent retrospective impact analysis provided a
complete report to Asthma UK, and an additional 300
page volume of supporting case studies.a
The objectives of this article are to describe the
methods and results of this evaluation of the impacts
from Asthma UK’s research (including how the difficul-
ties in assessing the range of impacts from such a com-
prehensive portfolio were addressed), and then to
discuss how the findings have been used by Asthma UK
to inform its research funding strategy.
Methods
Assessing the impacts of the full portfolio of a health re-
search funder requires a combination of methods. Those
applied in this study included a review of the data
already gathered by Asthma UK, a survey sent to the
researchers, and detailed case studies. However, such
methods are enhanced when informed by a conceptual
framework that can help organise the data collection,
analysis and reporting in as consistent a manner as
possible [8], in contrast to being a collection of one-off
case studies.
We therefore organised this project around an adapta-
tion of the HERG Payback Framework [5,11]. The frame-
work combines two aspects: a multi-dimensional
categorisation of benefits from health research and the
payback logic model. The multi-dimensional categorisa-
tion of benefits includes traditional categories such as the
knowledge production represented by publications,
research capacity building and the targeting of future
research. But it also incorporates wider impacts that are
increasingly viewed as important by research funders,
especially charitable patient organisations, including:
research was undertaken, and the motivations behind it.
Analysis here increases opportunities for identifying im-
pacts in the later payback categories, and attributing
them (at least partially) to the specific research funded.
Similarly, analysis at the interfaces between researchers
and research users can be important in understanding
how far impacts have been achieved. Previous studies
provide fuller accounts of the Payback Framework and
how it is applied to inform the methods used for data
collection, analysis and reporting when the focus has
been on selected case studies or on specific programmes
[5,8,11-13]. The study received appropriate ethical
approval from the University Research Ethics Committee
at Brunel University.
Survey
We adapted a survey used previously to examine the
impacts from the research funded by the Health
Technology Assessment programme in England [8], but
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includes clinical policies such as guidelines); health and
health sector benefits; and broader economic benefits.
The logic model is shown in Figure 1 and presents a sim-
plified version of the processes involved in commissioning
and undertaking the research, and in generating the full
range of impacts. It helps identify where the various
categories of impacts themselves might arise, but recog-
nises there is often considerable feedback between the dif-
ferent stages.
Pursuing the analysis through the various stages of the
logic model helps address attribution issues. The early
stages of the model focus on the context in which theFigure 1 The logic model of HERG’s Payback Framework used to orga
Hanney et al., 2004 [5].amended it to increase its relevance to Asthma UK. The
full survey can be seen as an additional file [see
Additional file 1]. For each project we identified publica-
tions already on Asthma UK’s database and inserted
them into the relevant survey. Respondents were then
asked to make any necessary amendments. Many of the
survey questions not only asked about whether certain
developments had occurred (for example, whether the
research led to any follow-on projects) but also asked
about the degree of influence on such decisions made by
the original research funded by the charity. This was in
recognition of the fact that just because Asthma UK
funding had been used to create scientific evidence, itnise the assessment of research impact. Source: Adapted from
did not guarantee that impact had been achieved in a
simple and linear manner, and it was desirable to
attempt to identify the level of the charity’s contribution.
We also wanted to make some calculation of the
amount of follow-on funding that might reasonably be
thought to have come from the original projects. There-
fore, we not only asked grant-holders to record the
funder of the follow-on research and the amount, but
also asked the responders to use one of three categories
(considerable/moderate/small) to describe the contribu-
tion to securing or informing the follow-on funding
made by the original Asthma UK funding.
We piloted the survey before sending it to all 153 lead
researchers (or principal investigators – PIs) awarded
project grants from 1996 (a date from which Asthma
UK held reasonable archival data) that had been com-
pleted by 2006, and to the ten researchers whose fellow-
ships had been completed. We recorded the survey
responses in an Access database, and developed innova-
tive analysis techniques for various issues. For example,
previous studies had just totalled the recorded amount
of follow-on funding but this was criticised as exaggerat-
ing the role of just one funder when several should
probably share the credit. Therefore, we not only asked
PIs to make an estimate of the contribution to the
funded research, but also made a best estimate of what
the categories ‘considerable’, ‘moderate’ and ‘small’ might
mean in quantitative terms. We took the amount of
follow-on funding recorded for projects and multiplied
it by the following proportions: considerable: 0.9; moder-
ate: 0.5; small: 0.1. This gave us a total of adjusted
follow-on funding for all the projects for which a survey
had been completed. We then calculated the total
funding supplied by Asthma UK for all the projects that
completed a survey, irrespective of whether or not the
PI reported any follow-on funding. Finally we calculated
the ratio of total follow-on funding (adjusted for the
contributions made and excluding the follow-on funding
that came from Asthma UK itself ) to original Asthma
UK funding.
Case studies
The project’s research team, in conjunction with the pro-
ject’s Advisory Committee, used information obtained
from the survey about claims for impact in the various
categories to inform the selection of nine projects and two
fellowships on which to undertake case studies – these are
listed on Table 1. We also wanted to conduct case studies
on the work of the two Asthma UK professorial chairs
who had been funded since 1988, and had, therefore been
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Table 1 Case studies on nine project grants and two fellow
Projec
Researcher: title and location at
time of proposal
Title of research (and ID)
Bradding, Dr. Peter. Glenfield Hospital,
University of Leicester
Human mast cell adhesion to br
Britton, Professor John. University of
Nottingham
Study of the role of parasites, du
aetiology of asthma and atopy i
Bush, Dr. Andrew. Imperial College,
London
Pathology of severe asthma in c
Durham, Professor Stephen. Imperial
College, London
Influence of grass pollen immun
lines: allergy or immune deviatio
Hawrylowicz, Dr. Catherine. King’s
College, London
IL-10: A critical regulator of inflam
023)
Hubbard, Dr. Richard. University of
Nottingham
A birth cohort study of the impa
therapies on the risk of pregnan
outcomes (04/019)
Johnston, Dr. Sebastian. University of
Southampton
Rhinovirus-induced regulation o
(332)
Pavord, Professor Ian. Glenfield
Hospital, University of Leicester
The immunopathology and cort
(02/036)
Sutton, Professor Brian. King’s College,
London
Structure based design of inhibi
Fello
Custovic, Dr. Adnan. University of
Manchester
Gene-environment interaction in
diseases (RF01C)Thomas, Dr Mike. University of
Aberdeen
Primary care asthma management:a key element in Asthma UK’s funding strategy, and on
ips
rants
Duration in
months
chial epithelium and airway smooth muscle (02/014) 24 (2003–05)
mite exposure and other environmental factors in the
rban and rural Ethiopia (98/014)
12 (1998–00)
ren (01/037) 23 (2001–03)
erapy (IT) on allergen-specific peripheral blood T-cell
(97/069)
24 (1997–99)
ation and glucocorticoid responsiveness in asthma (00/ 36 (2000–03)
of asthma, acute exacerbations of asthma and asthma
complications and adverse perinatal and paediatric
24 (2004–06)
hesion molecule expression in asthma exacerbations 24 (1996–98)
steroid responsiveness of non-eosinophilic asthma 24 (2002–05)
s of IgE binding to the mast cell receptor (97/033) 36 (1997–01)
hips
e development of atopy, asthma and other allergic 60 (2000–04)diagnosis, assessments and effective therapy (RF09T) 60 (2005–10)
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development.
In total, therefore, we undertook 14 case studies using
archival and documentary review, interviews and biblio-
metric analysis. There is inevitably a bias introduced into
the study by concentrating on case studies that are
thought likely to be positive examples. However, where
the main purpose of the case studies is to inform long-
term strategy through a richer analysis of the range of
impacts that arise - and how they manifest in different
payback categories over time - such cases need to have
sufficient content with which to explore what has
happened to Asthma UK-funded research.
For the project and fellowship case studies we
interviewed the PIs and also, where possible, one or two
further members of the relevant research team. As in
previous studies, we used a semi-structured interview
schedule informed by the Payback Framework. For all
the case studies we adopted a ‘rolling triangulation’ ap-
proach [14] in which we used the data gathered from
documentary and archival review, plus that from earlier
interviews, to inform the creation of a specific schedule
for each interview [see Additional file 2]. The Payback
Framework provided a conceptual framework to organ-
ise not only the data collection but also the analysis of
the data and its presentation in each case study.
For the case studies on the two professorial chairs and
the Centre, the Payback Framework again informed the
interview schedules and write-up. In these cases, how-
ever, we applied it in an innovative way to take account
of the breadth of topics covered, and to allow analysis of
how the nature of the funding (long-term in the case of
the chairs, and collaborative in the case of the Centre)
might facilitate the production of a range of impacts. Vari-
ous interviews were conducted for each of these three case
studies. In total, 15 interviewees helped inform the Centre
case study. They were: the two professorial chairs, who be-
came respectively Director and Deputy Director of the
Centre upon its creation in 2005; nine other members of
the Centre; and four independent experts.
As part of the case study analysis we searched major
national and international clinical guidelines related to
asthmab to see how far the Asthma UK-funded research
had influenced the clinical guidelines, which are
regarded as a form of clinical policy [14]. To obtain a
fuller idea of the contribution made by the Asthma
UK-funded research we took the analysis further than in
previous studies and on this occasion examined the num-
ber of times the relevant articles were cited in the guide-
line, the importance of specific points being supported
by Asthma UK-funded research, and how far the Asthma
UK-funded paper was the only, or key, evidence
supporting the relevant points. We also used a triangula-
tion approach as far as possible to inform the write-upof the case studies. A starting point for each case study
was the survey, but the archival and documentary review
and the interviews allowed claims made in the survey to
be checked and the issues further explored.
Case studies such as these on specific pieces of re-
search refer explicitly, and unavoidably, to the work of
identified individuals and teams. We therefore obtained
clearance for the text of each case study from the PI of
the project (fellowship or chair), and also from any other
interviewee whose interview evidence is used in an iden-
tifiable manner. This is not just a matter of courtesy, but
is an important aspect of ensuring the scientific quality
of the reported findings and ethical conduct of the
study.
Analysis of use of the report’s findings
The report was considered by Asthma UK as part of its
review of its research strategy. For this article the way in
which the report has been drawn upon by Asthma UK
was analysed by LM, using her position from within the
organisation.
Results
Ninety six surveys were returned (90 projects and six
fellowships) giving a response of 59% and we success-
fully completed the full complement of 14 case studies.
The findings of both the survey and case studies are
presented according to the categories of impact from the
Payback Framework, and then briefly summarised to
demonstrate the impact from each type of funding.
Impacts relating to each impact category
Knowledge production
The 90 projects recorded an average of four peer-
reviewed journal articles per project, but four of these
projects did not record producing any articles. There is
a possible bias in the results as there is some evidence
from Asthma UK’s database of publications, as described
in the full report (see End Notea), showing that the aver-
age number of publications already known to Asthma
UK is slightly higher for the projects on which surveys
were returned, than for those that were not. The re-
search fellows who completed the survey recorded an
average figure of 11 peer-reviewed articles. This higher
average figure reflects the view of some fellows that be-
cause their career at that time was being funded by
Asthma UK, all, or at least most, of their resulting publi-
cations could be counted as having some link with the
fellowship. Since their appointments in 1988, the two
Asthma UK professorial chairs, Tak Lee at King’s College
London, and Tim Williams, at Imperial College London,
published a total of over 500 publications.
For example, Tim Williams, conducted a major stream
of research in the search for the chemoattractants for
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as of considerable importance. Williams and his col-
leagues identified a potent endogenous chemoattractant
with high specificity for eosinophils. Williams named
this chemokine Eotaxin; the main paper describing it
was published in the Journal of Experimental Medicine
(Jose, 1994) [15] and has been cited over 600 times. It
has helped target considerable further research including
by Williams and his colleagues. They also successfully
sought patents on their work that they have been granted
worldwide on Eotaxin and antibodies to it. Further exam-
ples of key publications from Asthma UK-funded chairs,
projects and fellowships [16-18] are described in the case
studies summarized in Additional files 3, 4 and 5.
Research training and capacity building
The 90 PIs who completed surveys claimed that at least
62 higher degrees have been obtained or were expected
at least in part as a result of Asthma UK’s project
funding. An additional 15 are linked to the six fellow-
ships covered in this analysis. These 77 higher degrees
include 45 PhDs and 21 MDs. Asthma UK has now
funded PhD studentships at the MRC-Asthma UK
Centre (and several elsewhere jointly with the MRC).
According to the case study analysis, this is making an
important contribution to the substantial advances in
research training in asthma coming from the Centre.
In addition, the researchers from 64% of the funded pro-
jects that participated in the survey reported details of car-
eer development for at least one team member as a result
of the Asthma UK project funding. This included assisting
promotion for PIs, and also project researchers moving
forward to gain fellowships from major funders and con-
tinue their research in the asthma field.
Targeting further research and attracting further income for
asthma research
In total Asthma UK invested some £9.2 million in the 90
projects included in the analysis. The PIs claimed that
such investment helped to target, i.e. identify relevant re-
search questions for, 99 follow-on projects conducted by
themselves or members of their team. These follow-on
projects received almost £25 million in funding from
funders other than Asthma UK. However in the survey,
the PIs indicated that the intellectual contribution from
the original Asthma UK project to some of the largest
follow-on grants was often only moderate, or sometimes
small. Taking this into account, in the manner described
above, the £25 million of total follow-on funding could,
at a best estimate, be counted as equivalent to £12.9
million follow-on funding linked to Asthma UK’s £9.2
million original investment, So, every pound invested by
Asthma UK in the research projects funded between
1996 and 2006 is likely to have attracted at least £1.40 infollow-on research funding from sources other than
Asthma UK. In addition, in at least 35 cases, other
researchers were reported to have built on the findings
from the Asthma UK funded projects.
In some instances Asthma UK funding played a
‘pump-priming’ role, enabling the researcher to leverage
larger sums from other health research funding bodies, a
major example of which is described in the case study
on peptide-based immunotherapy research [18] [See
Additional file 5]. On occasions where Asthma UK itself
funded the follow-on research this has, at least in retro-
spect, amounted to a programme of work according to
survey and case study data. Sometimes these major
streams of work, involving a succession of project grants
from Asthma UK undertaken over many years (including
some dating back before 1996), have been important in
helping to move towards the wider impacts (policy or prod-
uct development, and health gains), often supplemented by
funding from other sources. Examples include the research
that started with an Asthma UK-funded project on IL-10
and glucocorticoid responsiveness in asthma which was
outlined on Asthma UK’s web site as follows: ‘A series of
Asthma UK funded projects led by Professor Catherine
Hawrylowicz in Professor Lee’s department has attracted
particular interest, as the work has resulted in a clinical trial
to explore whether vitamin D can improve the effectiveness
of steroid treatments for asthma in those who are normally
resistant to their benefits’ [19].
In a similar manner, the chairs directly brought in add-
itional funding for asthma research. Since 1995, Tak Lee
successfully applied for grants from the MRC, Wellcome
Trust and NHS R&D Programme alone worth about £6
million, in addition to the £2.7 million from the MRC to
the MRC-Asthma UK Centre. King’s College also made
considerable infrastructural investment into Lee’s de-
partment and the Centre. Overall Lee built up a substan-
tial research division. Similarly, Tim Williams secured
three major programme grants from the Wellcome Trust
to support his streams of asthma related research and
has secured university funding for various posts. Those
interviewed for the case study consistently claimed that
the creation of the MRC-Asthma UK Centre has helped
secure additional funding for asthma research. This is
both in terms of the core funding provided by the MRC
for additional facilities at the Centre, and the various
other ways in which PIs at the Centre are successfully
applying for funding (including through Asthma UK),
partly by demonstrating the strength of the environment
within which the research would be undertaken.
Informing policy development
In the survey just 13% of projects claimed to have made
an impact on policy already, and 17% expected such an
impact in the future. As part of the triangulation
Hanney et al. Allergy, Asthma & Clinical Immunology 2013, 9:17 Page 7 of 12
http://www.aacijournal.com/content/9/1/17process, checks were made of the impacts on guidelines
claimed in surveys by PIs of projects on which case
studies were later conducted. Generally exaggerated
claims had not been made. Indeed, the case studies often
identified additional examples of the research having
been cited on guidelines. On the basis of this analysis,
we broadly accepted the claims made in the surveys on
which case studies were not conducted.
According to the survey and case studies, three of the
six fellows claimed already to have made an impact on
policies and/or guidelines - longer-term salary funding
can allow fellows to develop a distinct role or focus
which lends itself more to policy development. For ex-
ample, a key paper by Mike Thomas [20] is already being
used in recent guidelines from the British Thoracic Society/
Association of Chartered Physiotherapists in Respiratory
Care [21] to support the use of breathing exercises for
improved control of asthma and quality of life.
Using the methods described above we were able to
establish that not only were papers from some Asthma
UK-funded research cited on international and national
guidelines, and other policy statements, but we also identi-
fied some examples when they supported key points and
were either the only evidence used to support the point,
or an important part of it. Some examples are given in the
case study on research on immunotherapy that was part
funded by Asthma UK [22,23] [see Additional file 4].
Other examples of national and/or international
guidelines (or specific sections) influenced by Asthma
UK-funded research, along with the Asthma UK-funded
paper cited in the guideline, include ones on: cough
[24,25]; asthma diagnosis in children [26,27]; and inhaled
corticosteroid resistance [26,28].
Whilst there are often time lags involved in achieving
an impact on policy, Asthma UK also supported some
explicit and successful attempts to provide evidence for
guidelines in areas in which there were gaps. In such sit-
uations there could be a rapid uptake of the findings.
For example, Richard Hubbard specifically applied to
Asthma UK for funding to develop stronger evidence on
the safety of asthma medicines during pregnancy, an
area where expert analysis of existing guidelines indi-
cated the evidence was weak [29]. The findings from this
project were published in late 2008 [30], and were
almost immediately incorporated into an update of the
2008 guidelines from the British Thoracic Society and
Scottish Intercollegiate Guidelines Network published in
June 2009 [31].
Informing product development
In the survey only a small minority of projects – just
17% - included in this research claim an impact on prod-
uct development already, and 31% claim to expect some
future impact. The impact on product developmentfrom Asthma UK projects and from chair funding takes
various forms, including helping to identify new roles
for existing products, contributing to the evidence base
for the development and application of major new drugs,
and contributing to new therapies being developed by
university spin-off companies.
In the stream of Asthma UK-funded projects on IL-10
and glucocorticoid responsiveness in asthma described
above, the important new therapy being tested – vitamin
D for steroid resistant asthma [32] – might involve using
existing products in a new way. The background and
significance of a stream of work in supporting the devel-
opment of anti-leukotriene medicines [16,33,34] is
explained in more detail in an additional file taken from
the case study on Tak Lee’s work as an Asthma UK pro-
fessorial chair [see Additional file 3].
Based on the projects included in this analysis, Asthma
UK-funded research has also contributed to product
development now being trialled by university spin-out
companies founded by the researchers in several cases.
The stream of research that showed T cell peptides have
potential in the treatment of cat allergies led to the
establishment of Circassia, an Imperial College London
spin-out company. The progress made, including suc-
cessful phase II trials, is described in an additional file
which provides further details about the research and
contains updates on the important findings published
from a subsequent joint Canadian/UK study that is con-
tinuing this stream of work [see Additional file 5].
Many years of research by Stephen Holgate and col-
leagues led to the ideas behind the development of
Interferon-beta treatment for rhinoviruses (common
cold infections) that cause many asthma exacerbations.
At a crucial time Asthma UK provided project funding
for Holgate that contributed to key advances, although
the MRC had supported much of the stream of work
[35]. The spin-out company, Synairgen, successfully
completed Phase 1 trials of the treatment and started
Phase II in March 2010 [36]. The significant further pro-
gress made after the formal end of the retrospective im-
pact analysis is described in the Discussion.
Health gain and broader economic benefits
Of the funded projects included in this research, again
only a small minority (10%) claim to have already made
an impact in any of the various forms this could take,
with 6% of projects believing they had made an impact
specifically in relation to health gains. Thirty-one per-
cent of projects suggested that they expected to make
some impact on health in the future, though it is
recognised that the time lags, and their unpredictable
nature, means a real impact on health gain can take
many years to materialise and is extremely difficult to
measure. Nevertheless, many of the examples described
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ing an impact on clinical policies, and on product devel-
opment, are likely already, or in future, to be leading to
health benefits. This is described in detail in the full re-
port on this impact analysis but a few key examples are
contained in Additional files 3, 4, and 5 which respect-
ively describe the health gains that have arisen from the
Asthma UK-funded contributions to research on leuko-
triene receptor antagonists [37] and on immunotherapy
for allergic rhinitis, and the potential health gains from
the research on peptide immunotherapy.
Health gains resulting from improved therapies are
likely to have broader economic benefits in terms of
reducing the working days lost through ill-health [2]. In
addition, school children sitting exams during the hay
fever season can suffer [38]; they might benefit from
immunotherapy.
There have also been broader economic benefits to the
UK from some of the cases of product development,
including from the work of Tim Williams, because UK
companies have been involved in undertaking some of
the development. Furthermore, the two spin-out com-
panies described above, Circassia and Synairgen, are UK
based.
A summary of impacts from each type of funding
The long-term funding for the professorial chairs has
resulted in many impacts across the full range of
payback categories, and the establishment of the MRC-
Asthma UK Centre is a major additional benefit that can
be at least partially attributed to the professorial chairs.
Interview and case study evidence suggests both chairs
showed considerable leadership in building up their
multi-disciplinary departments that formed core ele-
ments of the Centre.
The case study approach identified the success of the
MRC-Asthma UK Centre in Allergic Mechanisms of
Asthma in making scientific and medical breakthroughs,
training the next generation of scientists and doctors
focused on asthma research, promoting collaboration,
and attracting funding from other sources and increas-
ing the funds available for asthma research. Interview
evidence confirmed the documentary evidence from the
House of Lords Science and Technology Committee
which stated: ‘We visited a striking example of effective
collaboration at the MRC-Asthma UK Centre in Allergic
Mechanisms of Asthma’ [39]. Asthma UK’s strategy doc-
uments [6] help inform the Centre’s strategies. These
successes and the pioneering nature of the collaborative
Centre are further analysed in an additional file which
summarises key points from the case study based on the
Centre [see Additional file 6]. The creation of the Centre
reflects current thinking on the importance of both
translational health research, and the collaborationsbetween researchers and service providers and across
institutions and disciplines [40-42].
The medium-term funding for the fellowships enabled
some of them to develop a strand of research that made
a range of impacts. Various individual projects and fel-
lowships provided a very small return according to the
survey, but others contributed considerably according to
both the surveys and the case studies.
Discussion
As the only national charity dedicated to asthma in the
UK, Asthma UK commissioned HERG/RAND Europe to
apply the Payback Framework to a comprehensive analysis
of the various types of research funding traditionally pro-
vided by the charity in order to shape the charity’s future
research funding to maximise benefits for people with
asthma. Based on the funded projects included in this re-
search, it appears that Asthma UK’s previous research
funding approaches have made some important contribu-
tions to research returns in the full range of categories.
Whilst there are generally fewer impacts identified in the
difficult to measure, and time lag dependent, categories
such as impact on healthcare, some examples have been
described. Various individual projects and fellowships pro-
vided a very small return according to the survey (and, for
example the 13% of projects claiming to have made an im-
pact on policies is much lower than the 60% figure claimed
by primary studies funded in the English HTA
programme, which admittedly is much more oriented to
meeting the expressed needs of the NHS). Nevertheless,
some Asthma UK-funded projects contributed consider-
ably and the long-term funding of the professorial chairs
has led to many and varied impacts, including in part to
the establishment of the MRC-Asthma UK Centre.
The limitations of the study include the nature of the
survey which attempted to be comprehensive, but some
respondents thought it was too long and overall the re-
sponse was less than 60%. As noted, there is a possible
bias in the results as the average number of publications
already known to Asthma UK prior to the surveys was
slightly higher for the projects on which surveys were
returned, than for those that were not. Inevitably there
are also gaps in the data that can be collected, especially
through surveys. A possible limitation in the other direc-
tion is that if PIs have not fully answered all the ques-
tions there could be some underestimation of the
impacts, for example of the amount of follow-on
funding. Furthermore, there are variations in the extent
to which impacts have been demonstrated to result from
the specific funding provided by Asthma UK. Whilst
relying on PIs to complete surveys about their own re-
search is clearly a potential limitation, the limited
amount of evidence available from this study is in line
with that from previous studies which appears to
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correlation between the replies given and future funding,
researchers do not routinely exaggerate the impacts of
their research [8]. Important impacts have been reported
from the funding of professorial chairs, and also fellow-
ships, but it is difficult to assess how much of these im-
pacts should be attributed to Asthma UK funding.
Strengths of the study include the wide coverage of
Asthma UK research, which was achieved by sending a
survey to all fellows and to the PIs of projects funded
and completed over a 10 year time period. In addition,
the case studies provide detailed analysis of some of the
research funded by the charity. Some of the case studies
provide not only more detailed information than comes
from the surveys, but also examples of whole categories
of impact that had not been mentioned in the survey re-
sponse from the project. All aspects of the data collec-
tion, analysis and detailed write-up in the full report are
informed by the well-established Payback Framework
which is reported to be the most widely used approach
to assess the impacts from health research [8-10]. Previ-
ous reviews of studies assessing the impact from
programmes of health research [8] do not seem to re-
port a study that has combined such comprehensive
coverage of the work of diverse streams of funding from
one research funder with an analysis of the organisa-
tional mechanisms contributing to achieving the im-
pacts; given the overall objective of the study, this is
significant.
Use of the findings to inform Asthma UK’s strategy
Overall this analysis has given Asthma UK a unique
insight into its research and provided information to
guide its future strategy. It has also shown that a medical
research charity, even one with relatively modest funds,
can make some significant contributions - not just in
traditional areas such as knowledge production, but also
in health policies, product development and improved
healthcare. In particular, the analysis has highlighted to
Asthma UK:
▪ the importance of offering a diverse approach to
research funding to create a range of returns on
investment;
▪ the merits in terms of impacts of funding up-and-coming
scientists to establish them in their careers, and of
providing more costly long-term support to exceptional
senior research leaders who can pioneer large-scale
developments in a particular research field;
▪ the niche role that charitable patient organisations have
in providing key pump-priming funding to enable
leading researchers to make major breakthroughs that
they can then take to the larger general medical
research funders for more substantial support, which isparticularly important given the relatively small budget
available to Asthma UK to fund research;
▪ that Asthma UK’s investment into medical research
directly to improve the quality of life of people with
asthma, though important, has been relatively small; and
▪ that the success of the MRC-Asthma UK Centre in
Allergic Mechanisms of Asthma builds partly on
Asthma UK’s series of strategy documents, starting
with that from 2002 [6], which helped inform the
Centre’s strategies, and the creation of the Centre
reflects, and contributed to, current thinking on the
importance of translational health research and how
best to organise health research systems to meet the
needs of patients [40-42].
The findings of HERG’s evaluation placed Asthma UK
in a strong position to re-focus its efforts, define the
future vision for Asthma UK research, and publish its
2011–2016 research strategy. This strategy was informed
at an underpinning level by the results of HERG’s ana-
lysis in terms of the mechanisms the charity will employ
to fund research. One of the key features of the new re-
search strategy is the establishment of a second research
centre focused on improving the quality of life of people
with asthma, which will become known as the Asthma
UK Centre for Applied Research. Asthma UK wishes to
take the collaborative approach which worked so well with
the MRC-Asthma UK Centre and create a similar network
of leading researchers to develop large scale clinical trials
and other investigative studies across the UK.
Whilst the retrospective impact analysis was com-
pleted in time to feed into the revised research strategy
reported here, Asthma UK continues to monitor the
progress of, and be associated with, some of the most
successful developments. In the case of Synairgen the
findings from the Phase II trials received significant
media coverage in April 2012 because the inhaled drug
(SNG001) significantly reduced asthma symptoms dur-
ing the critical first week of infection and reduced the
number of exacerbations. According to Stephen Holgate,
quoted in the company’s press release: ‘This is a really
promising breakthrough for the future treatment of
asthma…. This trial is an important milestone in the
development of our SNG001 programme from its origins
in research supported by the MRC, Asthma UK, the
British Lung Foundation, the National Institute of Health
Research and the University of Southampton, to today’s
exciting results in this ‘real world’ asthma study’ [43].
The progress made by some of the examples of re-
search since the completion of the retrospective impact
analysis conducted for Asthma UK illustrates that the
relationship between analysing impact and revising the
research funding strategy is likely to be a continuing
process. The findings of such a retrospective impact
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iture, but as demonstrated here the retrospective analysis
can also inform the strategies for organisation of health
research with the aim of enhancing the level of wider
impacts achieved. Some previous applications of the
Payback Framework have examined the research impacts
from various streams of funding from the same research
funding organisation [12,44], and there is growing inter-
national interest in applying such approaches [45]. This
current application of the Framework to the research
funded by Asthma UK is more comprehensive in scope,
and, in relation to the professorial chairs, provides for
the first time, as far as the authors are aware, a detailed
analysis of how long-term chair funding can successfully
lead to the creation of an innovative Centre that aims to
translate research into improved patient care.
Conclusions
Research funders will continue to be interested in sys-
tematically analysing the full range of impacts from the
health research they fund. Through this piece of
research, we have demonstrated that adapted versions of
the Payback Framework can be used to conduct an
assessment of the outputs and societal impacts from a
portfolio of health research in a comprehensive way and,
more significantly, that these can be used not only to
help justify research expenditure but also to help inform
the strategy of health research funders.
We systematically show all types of Asthma UK’s re-
search funding assessed are making impacts at different
levels, with the chairs and pioneering collaborative
Centre being particularly significant. Whilst inevitably
only a minority of individual projects and fellowships
directly contributed to societal impacts, some of the re-
search portfolio is influencing asthma-related clinical
guidelines, and some contributing to product develop-
ment. The study’s findings, especially in relation to the
Centre, are being used to inform research funding strat-
egies to promote the achievement of impact.
Endnotes
aThe full report and volume of case studies describing
the retrospective impact analysis of Asthma UK-funded
research will eventually be made available on the
charity’s web site.
bMajor clinical guidelines reviewed included: British
Thoracic Society/Scottish Intercollegiate Guidelines Net-
work: British Guideline on the Management of Asthma
(2008, revised 2009); BSACI guidelines for the manage-
ment of allergic and non-allergic rhinitis (2008); The
European Pediatric Asthma Group: Diagnosis and treat-
ment of asthma in childhood: a PRACTALL consensus
report (2008); Chronic cough due to asthma: ACCP
evidence-based clinical practice guidelines (2006); Allergenimmunotherapy: A practice parameter (several editions
produced by the Joint Task Force on Practice Parameters
representing the American Academy of Allergy, Asthma
and Immunology; the American College of Allergy,
Asthma and Immunology; and the Joint Council of Allergy,
Asthma and Immunology); Allergic Rhinitis and its Impact
on Asthma (ARIA) 2008 Update (in collaboration with the
Word Health Organization, GA2LEN and AllerGen);
Global Strategy for the Diagnosis and Management of
Asthma in Children 5 Years and Younger, Global Inititative
for Asthma (2009).
Additional files
Additional file 1: Assessment of returns from research funded by
Asthma UK. Description: Survey used to gather data about Asthma UK-
funded projects and fellowships.
Additional file 2: Evaluating the returns from research funded by
Asthma UK. Basic semi-structured schedule for case study interview with
Principal Investigators that was amended to meet the circumstances of
each individual interview.
Additional file 3: Extract from case study on the impacts from Tak
Lee’s Asthma UK’s Professorial Chair funding: contribution to the
development of anti-leukotriene medicines and the treatment of
aspirin-sensitive asthma. Description: This is an extract from the full
case study on the range of impacts from Tak Lee’s Asthma UK’s
Professorial Chair funding, and focuses on just one of the areas in which
he made an important contribution - contribution to the development of
anti-leukotriene medicines and the treatment of aspirin-sensitive asthma.
Additional file 4: Asthma UK’s project funding: summary of case
study on contribution of Stephen Durham’s projects to the
evidence base supporting the use of immunotherapy. Description:
This is a summary of the full case study based on Asthma UK’s project
funding to support the research of Stephen Durham that made a major
contribution to the evidence base supporting the use of grass-pollen
immunotherapy.
Additional file 5: Asthma UK’s project/fellowship funding: account
of pump-priming research leading to successful early trials of
peptide immunotherapy and potential health gains. Description: This
is a version of the account in the main Impact analysis report to Asthma
UK that describes how Asthma UK’s project/fellowship funding played a
key pump-priming role in funding research that is leading to successful
early trials of peptide immunotherapy that has the potential to produce
health gains.
Additional file 6: Summary of case study on the emerging impacts
from the MRC-Asthma UK Centre in Allergic Mechanisms of Asthma.
Description: This is a summary of a few of the key points from the full
case study on the emerging impacts from the MRC-Asthma UK Centre in
Allergic Mechanisms of Asthma.
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